PredictAD

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades.

Alzheimer's disease (AD) covers 60-70% of all dementia cases. No cure for AD exists, and effective and reliable early diagnostic techniques are lacking. Early diagnosis and progress monitoring of AD is a central part of treatment once future drugs and prevention strategies become available. There is a strong indication that different biomarkers provide a reliable and early indication of AD prior to its major clinical signs. However, optimal early diagnosis requires information from a combination of different biomarkers to be used in a clinically useful way.

The objective of PredictAD is 1) to find the best combination of biomarkers for AD diagnostics from heterogeneous data (imaging, electrophysiology, molecular level, clinical tests, demographics) and 2) to develop clinically useful tools integrating the optimal biomarker results. Comprehensive biomarker discovery techniques and rigorous statistical models will be developed using the consortium's large databases. The accuracy and usability of models and tool will be clinically evaluated. The cost-effectiveness of heterogeneous data in AD diagnostic procedures will be studied.

By reaching its objectives, PredictAD provides an efficient and reliable solution for early AD diagnosis in clinical practice. The impacts on patients, their relatives and society are reduced suffering and costs. As we are living in the dawn of an era of new drugs and prevention strategies combined with increasing AD prevalence, now is the time to exploit the vast potential of information hiding in heterogeneous patient databases. PredictAD combines the best forces in Europe to solve the AD diagnostics problem, and hence strengthens EU leadership on the market.

For further information, please visit:
http://www.predictad.eu

Project co-ordinator:
Valtion teknillinen tutkimuskeskus VTT

Partners:

  • Nexstim Oy
  • Imperial College of Science, Technology and Medicine
  • Rigshospitalet
  • Kuopion yliopisto
  • Università degli Studi di Milano
  • GE Healthcare Ltd.
  • Uppsala universitet

Timetable: from 06/2008 – to 05/2011

Total cost: € 3.981.565

EC funding: € 2.891.526

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Virtual Humans Help Aspiring Doctors Lea…

For medical student Katie Goldrath, the first time delivering difficult health news came when she had to tell a young woman named Robin and her mom, Delmy, that Robin had...

Read more

'Smart Contact Lens Sensor' for Diabetic…

A recent study, affiliated with Ulsan National Institute of Science and Technology (UNIST), South Korea, has proposed the possibility of in situ human health monitoring simply by wearing a contact...

Read more

2017 eHealth Competition Awards SilverCl…

The eHealth Competition is an initiative that rewards the best digital health solutions produced by SMEs across Europe. This edition has been supported by Astrazeneca, Ship2B and Younoodle. This competition...

Read more

ECDC Report Shows Strong Potential of E-…

Twenty one EU/EEA countries have developed or are in the process of developing systems to digitally record information about vaccination, according to a new "ECDC survey report on immunisation information...

Read more

Devicare Raises 3 Million Euros in its C…

Devicare, a company specializing in innovative medical devices for chronic home care patients under Remote Patient Monitoring (RPM), has closed out a seed round of 3 million euros. This funding...

Read more

Successful Conclusion to conhIT 2017, th…

25 - 27 April 2017, Berlin, Germany. As conhIT, which took place from 25 to 27 April in Berlin, came to a close, 500 exhibitors, 9,500 participants from around the world...

Read more

Compiling Big Data in a Human-Centric Wa…

When a group of researchers in the Undiagnosed Disease Network at Baylor College of Medicine realized they were spending days combing through databases searching for information regarding gene variants, they...

Read more

Scopis Introduces the First Mixed-Realit…

Scopis, a company specializing in surgical navigation and medical augmented and mixed reality technologies, announced today the launch of its newest development, the Holographic Navigation Platform for use in surgery...

Read more

IMS MAXIMS Launches Vital Signs Mobile A…

Clinical technology specialist IMS MAXIMS will be launching its fully integrated vital signs application at eHealth Week on 3rd and 4th May in Olympia, London. Delegates will be the first...

Read more

Immunisation Information Systems in the …

Immunisation information systems (IIS) are defined as confidential, population-based, computerised databases that record all immunisation doses administered by participating providers to persons residing within a given geopolitical area. At the...

Read more

Abbott Announces CE Mark and First Use o…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify...

Read more

Using a Smartphone to Screen for Male In…

More than 45 million couples worldwide grapple with infertility, but current standard methods for diagnosing male infertility can be expensive, labor-intensive and require testing in a clinical setting. Cultural and...

Read more